Quoin Pharmaceuticals Ltd... (QNRX)
Quoin Pharmaceuticals Ltd. Statistics
Share Statistics
Quoin Pharmaceuticals Ltd. has 5.05M shares outstanding. The number of shares has increased by 135.73% in one year.
Shares Outstanding | 5.05M |
Shares Change (YoY) | 135.73% |
Shares Change (QoQ) | 77.2% |
Owned by Institutions (%) | 0.03% |
Shares Floating | 4.69M |
Failed to Deliver (FTD) Shares | 23.81K |
FTD / Avg. Volume | 0.44% |
Short Selling Information
The latest short interest is 19.17K, so 0.35% of the outstanding shares have been sold short.
Short Interest | 19.17K |
Short % of Shares Out | 0.35% |
Short % of Float | 0.49% |
Short Ratio (days to cover) | 0.2 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -0.19. Quoin Pharmaceuticals Ltd.'s PEG ratio is 0.
PE Ratio | 0 |
Forward PE | -0.19 |
PS Ratio | 0 |
Forward PS | 0 |
PB Ratio | 0 |
P/FCF Ratio | 0 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Quoin Pharmaceuticals Ltd..
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.57, with a Debt / Equity ratio of 0.
Current Ratio | 3.57 |
Quick Ratio | 3.57 |
Debt / Equity | 0 |
Debt / EBITDA | - |
Debt / FCF | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-2.99B |
Employee Count | 3 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -66.29% in the last 52 weeks. The beta is 1.59, so Quoin Pharmaceuticals Ltd.'s price volatility has been higher than the market average.
Beta | 1.59 |
52-Week Price Change | -66.29% |
50-Day Moving Average | 0.31 |
200-Day Moving Average | 0.55 |
Relative Strength Index (RSI) | 49.51 |
Average Volume (20 Days) | 5.46M |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | 0 |
Net Income | -8.96B |
EBITDA | 0 |
EBIT | n/a |
Earnings Per Share (EPS) | -1911.5 |
Balance Sheet
The company has 3.62B in cash and 0 in debt, giving a net cash position of 3.62B.
Cash & Cash Equivalents | 3.62B |
Total Debt | 0 |
Net Cash | 3.62B |
Retained Earnings | -55.17B |
Total Assets | 15.71B |
Working Capital | 10.75B |
Cash Flow
In the last 12 months, operating cash flow was -7.86B and capital expenditures 0, giving a free cash flow of -7.86B.
Operating Cash Flow | -7.86B |
Capital Expenditures | 0 |
Free Cash Flow | -7.86B |
FCF Per Share | -1675.79 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
QNRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for QNRX is $4, which is 1233.3% higher than the current price. The consensus rating is "Buy".
Price Target | $4 |
Price Target Difference | 1233.3% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Apr 8, 2025. It was a backward split with a ratio of 1:20.
Last Split Date | Apr 8, 2025 |
Split Type | backward |
Split Ratio | 1:20 |
Scores
Altman Z-Score | -4.1 |
Piotroski F-Score | 1 |